table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderate
COVID-19 mild to moderate
anticoagulant X-COVID-19
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...

0 studies excluded by filtering options 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons